GSK takes NICE risk with Votrient for RCC
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has recommended GlaxoSmithKline's targeted oral anticancer Votrient (pazopanib) as a new first-line treatment for NHS patients with advanced renal cell carcinoma (RCC). The recommendation hinged on a two-part patient access scheme, which could involve a rebate for the NHS depending on forthcoming trial results.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.